Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), announces it has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical (“Endpoint”) and Fortrea Patient Access businesses, to Arsenal Capital Partners (“Arsenal”), a leading private equity firm specializing in building market-leading, technology-rich healthcare companies. Endpoint operates in the high growth eClinical market as a leading provider of Randomization and Trial Supply Management (RTSM) solutions to biopharmaceutical and CRO customers with expertise in serving complex and late-stage clinical trials. Fortrea Patient Access is a scaled leader in the HUB services and patient access market.
Read the full article: Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners //
Source: https://www.globenewswire.com/news-release/2024/03/11/2843576/0/en/Fortrea-Signs-Definitive-Agreement-to-Divest-Endpoint-Clinical-and-Patient-Access-Businesses-to-Arsenal-Capital-Partners.html